person · Reporting owner

Hack Andrew A. F.

Disclosed activity across 7 companies

Tapewire entity: 69988
SEC CIK: 0001657434

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allena Pharmaceuticals, Inc.ALNA · Entity 130904	Director	November 17, 2020	November 18, 2020
Atea Pharmaceuticals, Inc.AVIR · Entity 5580	Director	November 03, 2020	November 04, 2020
BCLS Acquisition Corp.BLSA · Entity 145747	Director · Chief Financial Officer · 10% owner	October 26, 2020	October 26, 2020
DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930	Director	August 08, 2023	August 10, 2023
Editas Medicine, Inc.EDIT · Entity 5502	Chief Financial Officer	February 04, 2019	February 06, 2019
Nuvalent, Inc.NUVL · Entity 29892	Director	December 11, 2024	December 13, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allena Pharmaceuticals, Inc.

Report date November 17, 2020 · Filed November 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2030-11-16	Direct	14,000	Reported balance After 2020-11-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-11-17 · Grant · Acquired 14,000 · Balance 14,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.

Atea Pharmaceuticals, Inc.

Report date November 03, 2020 · Filed November 04, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	5,615,659	Last balance in matching sequence After 2020-11-03 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-11-03 · Conversion · Acquired 5,365,659 · Balance 5,365,659 F3: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Row 2 · 2020-11-03 · Purchase · Acquired 250,000 · Balance 5,615,659 F4: On November 3, 2020, BCLS II Investco purchased 250,000 shares of common stock of the Issuer at a price of $24.00 per share, pursuant to an underwritten public offering. F1: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-03 · Conversion · Disposed 3,383,190 · Balance 0 F3: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Series D-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-03 · Conversion · Disposed 1,982,469 · Balance 0 F3: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities").

F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F3: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F4: On November 3, 2020, BCLS II Investco purchased 250,000 shares of common stock of the Issuer at a price of $24.00 per share, pursuant to an underwritten public offering.

BCLS Acquisition Corp.

Report date October 26, 2020 · Filed October 26, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A ordinary sharesSEC Table I · non-derivative	IndirectSee Footnote	487,500	Reported balance After 2020-10-26 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-26 · Grant · Acquired 487,500 · Balance 487,500 F1: The reported Class A ordinary shares were purchased from the Issuer in a private placement by BCLS Acquisition Holdings, LP (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-249284). F2: The shares are held by the Sponsor. The Sponsor is controlled by its general partner, BCLS Acquisition Holdings (GP), LLC (the "General Partner"), which is governed by a board of managers consisting of three managers. Each manager has one vote, and the approval of a majority of the managers is required to approve an action on behalf of the Sponsor. Andrew Hack serves on the board of managers of the General Partner. As a result, Dr. Hack may be deemed to share beneficial ownership of the shares held by the Sponsor. Dr. Hack disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported Class A ordinary shares were purchased from the Issuer in a private placement by BCLS Acquisition Holdings, LP (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-249284).

F2: The shares are held by the Sponsor. The Sponsor is controlled by its general partner, BCLS Acquisition Holdings (GP), LLC (the "General Partner"), which is governed by a board of managers consisting of three managers. Each manager has one vote, and the approval of a majority of the managers is required to approve an action on behalf of the Sponsor. Andrew Hack serves on the board of managers of the General Partner. As a result, Dr. Hack may be deemed to share beneficial ownership of the shares held by the Sponsor. Dr. Hack disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

DYNAVAX TECHNOLOGIES CORP

Report date August 08, 2023 · Filed August 10, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	915,000	Reported balance After 2023-08-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-08-08 · Sale · Disposed 1,500,000 · Balance 915,000 F1: Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	10,714	Reported balance Holding disclosure · report date 2023-08-08 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,714

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Editas Medicine, Inc.

Report date February 04, 2019 · Filed February 06, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2019-02-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-02-04 · Exercise / conversion · Acquired 6,895 · Balance 6,895 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 28, 2018. Row 2 · 2019-02-04 · Sale · Disposed 6,895 · Balance 0 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 28, 2018. F2: This transaction was executed in multiple trades at prices ranging from $21.16 to $21.805. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2025-09-13	Direct	9,618	Reported balance After 2019-02-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-02-04 · Exercise / conversion · Disposed 6,895 · Balance 9,618 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 28, 2018. F3: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 28, 2018.

F2: This transaction was executed in multiple trades at prices ranging from $21.16 to $21.805. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.

Nuvalent, Inc.

Report date December 11, 2024 · Filed December 13, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnotes	1,447,267	Reported balance After 2024-12-11 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-12-11 · Sale · Disposed 1,250,000 · Balance 1,447,267 F1: Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities"). F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	Direct	2,499	Reported balance Holding disclosure · report date 2024-12-11 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,499

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities").

F2: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mersana Therapeutics, Inc.

Report date January 06, 2026 · Filed January 06, 2026

Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-01-06 transaction · row 1 1 source row Row 1 · 2026-01-06 · Other · Disposed 578 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2026-01-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-01-06 · Other · Disposed 346,545 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5: Represents shares of Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS II and BCIPLS, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by the Bain Capital Life Sciences Entities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08	Direct	Reported balance After 2026-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-01-06 · Disposition to issuer · Disposed 2,460 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.00	Direct	Reported balance After 2026-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-06 · Disposition to issuer · Disposed 2,088 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $306.75	Direct	Reported balance After 2026-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-06 · Disposition to issuer · Disposed 400 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.75	Direct	Reported balance After 2026-01-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-06 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $572.50	Direct	Reported balance After 2026-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-06 · Disposition to issuer · Disposed 368 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $527.25	Direct	Reported balance After 2026-01-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-06 · Disposition to issuer · Disposed 118 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $372.50	Direct	Reported balance After 2026-01-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-06 · Disposition to issuer · Disposed 1,002 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.00	Direct	Reported balance After 2026-01-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-06 · Disposition to issuer · Disposed 439 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.50	Direct	Reported balance After 2026-01-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $216.00	Direct	Reported balance After 2026-01-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-01-06 · Disposition to issuer · Disposed 734 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50	Direct	Reported balance After 2026-01-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-01-06 · Disposition to issuer · Disposed 2,200 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

F5: Represents shares of Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS II and BCIPLS, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by the Bain Capital Life Sciences Entities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 26, 2018 Filed Jan 8, 2019 22:32 UTC Amendment	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001179110-19-000574 · edgar.xml · derivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,427 Underlying: Common Stock · 6,000 shares Expires 2025-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Reporting Person is filing this amended Form 4 to amend the Form 4 filed by the Reporting Person with the SEC on October 30, 2018, which inadvertently reported the exercise of a different stock option held by the Reporting Person. This amended Form 4 now reflects the correct information regarding the option that was exercised. F2 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. F3 · derivative.exercise_date: This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
October 26, 2018 Filed Jan 8, 2019 22:32 UTC Amendment	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	6,000	$3.23	$19,380.00	Disclosure SEC source: 0001179110-19-000574 · edgar.xml · nonDerivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Reporting Person is filing this amended Form 4 to amend the Form 4 filed by the Reporting Person with the SEC on October 30, 2018, which inadvertently reported the exercise of a different stock option held by the Reporting Person. This amended Form 4 now reflects the correct information regarding the option that was exercised. F2 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:02 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-011848 · edgar.xml · derivative · entry 3 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,513 Underlying: Common Stock · 8,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. F3 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:02 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	8,000	$32.08	$256,640.00	Disclosure SEC source: 0001179110-18-011848 · edgar.xml · nonDerivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.73 to $32.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:02 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	8,000	$6.48	$51,840.00	Disclosure SEC source: 0001179110-18-011848 · edgar.xml · nonDerivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. Read SEC document
September 20, 2018 Filed Sep 21, 2018 20:00 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $12.27	$0.00	Disclosure SEC source: 0001104659-18-058009 · a4.xml · derivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2019 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
August 31, 2018 Filed Sep 5, 2018 20:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001182489-18-000336 · edgar.xml · derivative · entry 3 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,513 Underlying: Common Stock · 10,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. F3 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
August 31, 2018 Filed Sep 5, 2018 20:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	10,000	$32.23	$322,300.00	Disclosure SEC source: 0001182489-18-000336 · edgar.xml · nonDerivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.84 to $32.58. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 31, 2018 Filed Sep 5, 2018 20:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	10,000	$6.48	$64,800.00	Disclosure SEC source: 0001182489-18-000336 · edgar.xml · nonDerivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 29, 2018. Read SEC document
June 08, 2018 Filed Jun 12, 2018 16:13 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	GrantStock Option (Right to Buy) · Derivative	20,364	$0.00 Strike: $13.52	$0.00	Disclosure SEC source: 0001209191-18-037216 · doc4.xml · derivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,364 Underlying: Common Stock · 20,364 shares Expires 2028-06-07 F1 · derivative.exercise_date: Stock option shall vest in equal annual installments over the three years following the grant date; provided that, if not already vested, such stock option shall vest and become fully exercisable on the date of the third annual meeting of stockholders following the grant date. Read SEC document
June 04, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	3,000	$0.00 Strike: $24.60	$0.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · derivative · entry 8 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 3,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. F5 · derivative.exercise_date: This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021. Read SEC document
June 04, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	3,000	$37.10	$111,300.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · nonDerivative · entry 6 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. Read SEC document
June 04, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	3,000	$24.60	$73,800.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · nonDerivative · entry 5 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. Read SEC document
June 01, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · derivative · entry 7 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,513 Underlying: Common Stock · 7,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. F4 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
June 01, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	2,000	$39.86	$79,720.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · nonDerivative · entry 4 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $39.6 to $40.17. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	2,000	$6.48	$12,960.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · nonDerivative · entry 3 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. Read SEC document
June 01, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	5,000	$39.05	$195,250.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · nonDerivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.6 to $39.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2018 Filed Jun 5, 2018 20:08 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	5,000	$6.48	$32,400.00	Disclosure SEC source: 0001179110-18-008052 · edgar.xml · nonDerivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	22,000	$0.00 Strike: $24.60	$0.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · derivative · entry 14 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,500 Underlying: Common Stock · 22,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · derivative · entry 13 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,513 Underlying: Common Stock · 6,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F7 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. F8 · balance_after: This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	22,000	$37.91	$834,020.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 10 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · price: This transaction was executed in multiple trades at prices ranging from $37.86 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	22,000	$24.60	$541,200.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 9 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	1,000	$38.39	$38,390.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 8 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $38.23 to $38.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	1,000	$6.48	$6,480.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 7 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	5,000	$37.51	$187,550.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 6 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $37.13 to $38.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 20, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	5,000	$6.48	$32,400.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 5 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
March 19, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · derivative · entry 12 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,513 Underlying: Common Stock · 6,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F7 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. F8 · balance_after: This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018. Read SEC document
March 19, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	6,000	$37.65	$225,900.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 4 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.29 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 19, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	6,000	$6.48	$38,880.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 3 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
March 16, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · derivative · entry 11 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,513 Underlying: Common Stock · 6,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F7 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. F8 · balance_after: This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018. Read SEC document
March 16, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	6,000	$39.43	$236,580.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.02 to $40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 16, 2018 Filed Mar 20, 2018 21:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	6,000	$6.48	$38,880.00	Disclosure SEC source: 0001179110-18-004702 · edgar.xml · nonDerivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
February 16, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · derivative · entry 9 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,662 Underlying: Common Stock · 6,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F5 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
February 16, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	6,000	$35.32	$211,920.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · nonDerivative · entry 6 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $34.82 to $35.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 16, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	6,000	$6.48	$38,880.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · nonDerivative · entry 5 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
February 15, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · derivative · entry 8 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,662 Underlying: Common Stock · 6,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F5 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
February 15, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	6,000	$34.61	$207,660.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · nonDerivative · entry 4 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.50 to $34.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 15, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	6,000	$6.48	$38,880.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · nonDerivative · entry 3 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
February 14, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · derivative · entry 7 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,662 Underlying: Common Stock · 6,000 shares Expires 2025-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F5 · derivative.exercise_date: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
February 14, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	6,000	$32.71	$196,260.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · nonDerivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.27 to $33.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 14, 2018 Filed Feb 16, 2018 21:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	6,000	$6.48	$38,880.00	Disclosure SEC source: 0001179110-18-002253 · edgar.xml · nonDerivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. Read SEC document
February 07, 2018 Filed Feb 9, 2018 22:22 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	95,000	$0.00 Strike: $36.67	$0.00	Disclosure SEC source: 0001179110-18-001906 · edgar.xml · derivative · entry 1 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2028-02-06 F1 · derivative.exercise_date: This option was granted on February 7, 2018 and is scheduled to vest over four years in equal monthly installments beginning on February 7, 2018 through February 7, 2022. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	4,649	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · derivative · entry 9 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,427 Underlying: Common Stock · 4,649 shares Expires 2025-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F5 · derivative.exercise_date: This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	4,649	$25.06	$116,510.45	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · nonDerivative · entry 6 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.75 to $25.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected Read SEC document
December 19, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	4,649	$3.23	$15,016.27	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · nonDerivative · entry 5 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · derivative · entry 8 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,076 Underlying: Common Stock · 5,000 shares Expires 2025-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F5 · derivative.exercise_date: This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	5,000	$24.68	$123,409.00	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · nonDerivative · entry 4 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $24.50 to $25.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionCommon Stock	5,000	$3.23	$16,150.00	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · nonDerivative · entry 3 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document
December 15, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $3.23	$0.00	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · derivative · entry 7 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,076 Underlying: Common Stock · 5,000 shares Expires 2025-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F5 · derivative.exercise_date: This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. Read SEC document
December 15, 2017 Filed Dec 19, 2017 21:38 UTC	Editas Medicine, Inc. EDIT · Entity 5502	SaleCommon Stock	5,000	$24.31	$121,546.00	Disclosure SEC source: 0001179110-17-015633 · edgar.xml · nonDerivative · entry 2 Hack Andrew A. F. · CIK 0001657434 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.20 to $24.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.